In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are ...
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...
In the Asia-Pacific region, Japan is currently reviewing a regulatory submission for the antibody in NDMM subjects who are not eligible for haematopoietic stem cell transplantation. Sarclisa has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback